Piramal Pharma shines on commencing commercial production of Sevoflurane at Telangana facility
Piramal Pharma is currently trading at Rs. 232.70, up by 4.75 points or 2.08% from its previous closing of Rs. 227.95 on the BSE.
The scrip opened at Rs. 234.05 and has touched a high and low of Rs. 241.00 and Rs. 230.95 respectively. So far 179621 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 307.85 on 06-Nov-2024 and a 52 week low of Rs. 132.05 on 15-Apr-2024.
Last one week high and low of the scrip stood at Rs. 241.00 and Rs. 218.60 respectively. The current market cap of the company is Rs. 30817.02 crore.
The promoters holding in the company stood at 34.95%, while Institutions and Non-Institutions held 45.78% and 19.27% respectively.
Piramal Pharma has commenced commercial production of Sevoflurane at the company’s facility located at Digwal, Telangana, India. This was achieved by creating capacity for Sevoflurane manufacture at the Digwal facility in addition to existing capabilities at the company’s facility at Bethlehem, Pennsylvania, USA. This would boost the company’s capability to also tap into inhalation anesthesia opportunities in the ROW markets in addition to the USA markets.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
